Virksomhedsstatus | NORMAL. |
Sidst opdateret den 13.05.2022 og
angivet som gældende fra 13.05.2022 (717
dage). |
Ingen historik.
Branche | Forskning og eksperimentel udvikling indenfor bioteknologi (721100). |
Sidst opdateret den 13.05.2022 og
angivet som gældende fra 13.05.2022 (717
dage). |
Ingen historik.
Revisionfravalgt | false. |
Sidst opdateret den 13.05.2022 og
angivet som gældende fra 13.05.2022 (717
dage). |
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
Navne | Zevra Denmark A/S. |
Sidst opdateret den 22.02.2023 og
angivet som gældende fra 22.02.2023 (432
dage). |
Historik | Start | Stop |
---|
Zevra Denmark A/S | 22.02.2023 | |
KemPharm Denmark A/S | 13.05.2022 | 21.02.2023 |
Tegningsregel | Selskabet tegnes af én direktør. |
Sidst opdateret den 13.05.2022 og
angivet som gældende fra 13.05.2022 (717
dage). |
Fortolkning
(1 tegningsmulighed)
| 1 direktør |
Ingen historik.
Type af revisorbistand:Auditor's report on audited financial statements
Navn på revisionsvirksomhed:EY Godkendt Revisionspartnerselskab
Revisionsvirksomhedens CVR-nr.:30700228
Beskrivelse af revisor:State Authorised Public Accountants
Virksomhedens regnskabsklasse:Reporting class B
Grundlag for konklusion (revision):We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Konklusion (revision):We have audited the financial statements of Zevra Denmark A/S for the financial year 13 May – 31 December 2022, which comprise income statement, balance sheet, statement of changes in equity and notes, including accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act. In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2022 and of the results of the Company's operations for the financial year 13 May – 31 December 2022 in accordance with the Danish Financial Statements Act.
Udtalelse om ledelsesberetningen (revision):Management is responsible for the Management's review. Our opinion on the financial statements døs not cover the Management's review, and we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated. Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act. Based on the work we have performed, we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of the Management's review.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.